Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MDM2 over exp TP53 wild-type |
| Therapy | KRT-232 + Pembrolizumab |
| Indication/Tumor Type | ovarian clear cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MDM2 over exp TP53 wild-type | ovarian clear cell carcinoma | predicted - sensitive | KRT-232 + Pembrolizumab | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian clear cell carcinoma cell line harboring wild-type TP53 and MDM2 overexpression was sensitive to combination treatment with KRT-232 (AMG 232) and Keytruda (pembrolizumab) when co-cultured with T cells, demonstrating increased T-cell mediated cell death (PMID: 32655895). | 32655895 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32655895) | AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. | Full reference... |